Novel therapeutic strategies targeting the epidermal growth factor receptor (EGFR) family and its downstream effectors in breast cancer

被引:89
作者
Atalay, G [1 ]
Cardoso, F [1 ]
Awada, A [1 ]
Piccart, MJ [1 ]
机构
[1] Inst Jules Bordet, Dept Med Oncol, B-1000 Brussels, Belgium
关键词
Akt; breast cancer; EGFR (ErbB) family; HER-2; MAPK;
D O I
10.1093/annonc/mdg365
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
From the early experience with tamoxifen to the current use of Herceptin, targeted therapy has been proven to be an important part of breast cancer (BC) treatment. In the last decade, advances in molecular biology have allowed scientists to design highly individualized, 'smart' pharmaceuticals, capable of manipulating the growth factor pathways and the genes that are involved in the development and maintenance of the malignant phenotype. The epidermal growth factor receptor (EGFR) family, as one of the best studied growth factor pathways in cancer, resembles a 'treasure island' by providing a wide range of biologically relevant targets involved in breast carcinogenesis. While a large number of new agents targeting this pathway are continuingly being tested in preclinical experiments, clinicians are witnessing the migration of some of these agents to daily practice. The aim of this review is to provide clinicians with an updated synopsis of the most advanced anti-erbB therapeutic strategies with activity against BC.
引用
收藏
页码:1346 / 1363
页数:18
相关论文
共 189 条
[1]  
Adams J, 1999, CANCER RES, V59, P2615
[2]  
Adjei A. A., 2000, P ASCO, V19, P722
[3]   Blocking oncogenic Ras signaling for cancer therapy [J].
Adjei, AA .
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2001, 93 (14) :1062-1074
[4]   Targeting ligand-activated ErbB2 signaling inhibits breast and prostate tumor growth [J].
Agus, DB ;
Akita, RW ;
Fox, WD ;
Lewis, GD ;
Higgins, B ;
Pisacane, PI ;
Lofgren, JA ;
Tindell, C ;
Evans, DP ;
Maiese, K ;
Scher, HI ;
Sliwkowski, MX .
CANCER CELL, 2002, 2 (02) :127-137
[5]  
Albain K, 2002, BREAST CANCER RES TR, V76, pS33
[6]   Potential benefits of the irreversible pan-erbB inhibitor, CI-1033, in the treatment of breast cancer [J].
Allen, LF ;
Lenehan, PF ;
Eiseman, IA ;
Elliott, WL ;
Fry, DW .
SEMINARS IN ONCOLOGY, 2002, 29 (03) :11-21
[7]   Heregulin induces phosphorylation of BRCA1 through phosphatidylinositol 3-kinase/AKT in breast cancer cells [J].
Altiok, S ;
Batt, D ;
Altiok, N ;
Papautsky, A ;
Downward, J ;
Roberts, TM ;
Avraham, H .
JOURNAL OF BIOLOGICAL CHEMISTRY, 1999, 274 (45) :32274-32278
[8]   ZD1839 (Iressa), a novel epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor, potently inhibits the growth of EGFR-positive cancer cell lines with or without erbB2 overexpression [J].
Anderson, NG ;
Ahmad, T ;
Chan, K ;
Dobson, R ;
Bundred, NJ .
INTERNATIONAL JOURNAL OF CANCER, 2001, 94 (06) :774-782
[9]  
Arteaga CL, 2002, ONCOLOGIST, V7, P31
[10]   MAP kinase/estrogen receptor cross-talk enhances estrogen-mediated signaling and tumor growth but does not confer tamoxifen resistance [J].
Atanaskova, N ;
Keshamouni, VG ;
Krueger, JS ;
Schwartz, JA ;
Miller, F ;
Reddy, KB .
ONCOGENE, 2002, 21 (25) :4000-4008